111 related articles for article (PubMed ID: 37738842)
1. Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma.
Zhang Q; Zhang J; Tian Y; Wang J; Jin G; Liu F
Virology; 2023 Oct; 587():109885. PubMed ID: 37738842
[TBL] [Abstract][Full Text] [Related]
2. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.
Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F
Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem cells loaded with Ad5-Ki67/IL-15 enhance oncolytic adenovirotherapy in experimental glioblastoma.
Wang P; Zhang J; Zhang Q; Liu F
Biomed Pharmacother; 2023 Jan; 157():114035. PubMed ID: 36434955
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells.
Zhang Q; Zhang J; Tian Y; Zhu G; Liu S; Liu F
Cell Biosci; 2020; 10():124. PubMed ID: 33133514
[TBL] [Abstract][Full Text] [Related]
5. TS-2021, a third-generation oncolytic adenovirus that carried Ki67 promoter, TGF-β2 5'UTR, and IL-15 against experimental glioblastoma.
Wang J; Zhang J; Zhang Q; Zhang W; Zhang Q; Jin G; Liu F
J Med Virol; 2024 Jan; 96(1):e29335. PubMed ID: 38149454
[TBL] [Abstract][Full Text] [Related]
6. The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.
Klawitter M; El-Ayoubi A; Buch J; Rüttinger J; Ehrenfeld M; Lichtenegger E; Krüger MA; Mantwill K; Koll FJ; Kowarik MC; Holm PS; Naumann U
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077380
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma.
Chen L; Zhou C; Chen Q; Shang J; Liu Z; Guo Y; Li C; Wang H; Ye Q; Li X; Zu S; Li F; Xia Q; Zhou T; Li A; Wang C; Chen Y; Wu A; Qin C; Man J
Mol Ther Oncolytics; 2022 Mar; 24():522-534. PubMed ID: 35229030
[TBL] [Abstract][Full Text] [Related]
8. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
9. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
Zhang J; Guo Y; Fang H; Guo X; Zhao L
Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
[TBL] [Abstract][Full Text] [Related]
11. An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition.
Sun Y; Zhang Z; Zhang C; Zhang N; Wang P; Chu Y; Chard Dunmall LS; Lemoine NR; Wang Y
Mol Ther Oncolytics; 2022 Sep; 26():105-119. PubMed ID: 35795092
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
[TBL] [Abstract][Full Text] [Related]
13. Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity.
Qi Z; Zhao J; Li Y; Zhang B; Hu S; Chen Y; Ma J; Shu Y; Wang Y; Cheng P
Front Immunol; 2023; 14():982180. PubMed ID: 37114043
[TBL] [Abstract][Full Text] [Related]
14. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.
Qiao J; Dey M; Chang AL; Kim JW; Miska J; Ling A; M Nettlebeck D; Han Y; Zhang L; Lesniak MS
Oncoimmunology; 2015 Aug; 4(8):e1022302. PubMed ID: 26405578
[TBL] [Abstract][Full Text] [Related]
16. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.
Li M; Li G; Kiyokawa J; Tirmizi Z; Richardson LG; Ning J; Das S; Martuza RL; Stemmer-Rachamimov A; Rabkin SD; Wakimoto H
Acta Neuropathol Commun; 2020 Dec; 8(1):221. PubMed ID: 33308315
[TBL] [Abstract][Full Text] [Related]
17. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
[TBL] [Abstract][Full Text] [Related]
20. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
Belcaid Z; Berrevoets C; Choi J; van Beelen E; Stavrakaki E; Pierson T; Kloezeman J; Routkevitch D; van der Kaaij M; van der Ploeg A; Mathios D; Sleijfer S; Dirven C; Lim M; Debets R; Lamfers MLM
Neurooncol Adv; 2020; 2(1):vdaa011. PubMed ID: 32642679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
